Phoenix, Arizona (PRWEB) June 02, 2016
Bioscience Americas, LLC (http://www.bioscienceamericas.com), the world’s leading developer of autologous, or adult, stem cell treatment centers, announced today the creation of a new division entitled Bioscience High Performance (BHP).
Complementing the Company’s existing business model providing stem cell treatments for autoimmune diseases and rejuvenation therapies primarily through medical tourism, the new division will focus on working with professional athletes and sports teams in the United States, Canada, and Latin America.
Bioscience Americas CEO Eric Stoffers said that BHP is poised to serve what he characterized as a vast market to treat athletic injuries such as orthopedic impairments, and muscle and ligament strains and tears.
“Stem cell therapies have proven successful for many professional athletes during their playing years. Many retired athletes have also been treated with stem cell to help heal old sports injuries," Mr. Stoffers said.
The new BHP division will focus marketing efforts on making athletes both here in the U.S. and Canada, and throughout Latin America more aware of the benefits of stem cell to treat sports injuries.
Bioscience High Performance will be headed by Randy Broadus, a well-known marketing executive based in Louisville, Kentucky. Mr. Broadus has more than twenty-five years of high-level experience in sports and entertainment marketing. He formerly served as vice president of player relations with the Allied Marketing Group, an Indianapolis-based sports management agency and as a broadcast executive with the Indiana Pacers of the NBA.
In commenting on the appointment, Bill Deegan, Bioscience Americas President, said, “Randy’s passion for sports, coupled with his knowledge of the benefits of stem cell treatments and the advances in sports medicine will make him an excellent addition to the Bioscience Americas team.”
Bioscience Americas, based in Phoenix, Arizona, is the international development partner of the Global Institute of Stem Cell Therapy and Research (GIOSTAR).
GIOSTAR is a consortium of renowned stem cell scientists and is based at the University of California Medical Center in San Diego, California. GIOSTAR has been the recipient for more than $400 million in research grants, endowment contributions, and legislative appropriations to further its pioneering research using autologous stem cells.
Bioscience Americas and GIOSTAR are jointly developing a stem cell treatment facility to be located within San Vicente Hospital in Medellin, Colombia. The Bioscience Americas and GIOSTAR business plan calls for the addition of two more stem cell facilities in South America. Future expansion plans also include locating hospital related treatment facilities in Costa Rica and Mexico, and on Native American tribal land within the United States.